Education
About Us
Working with TipRanks
Follow Us
Galera Therapeutics, Inc. (GRTX)
:GRTX
Top Page
Galera Therapeutics
(OTC:GRTX)
31Underperform
Galera Therapeutics (GRTX) vs. S&P 500 (SPY)
Market Cap
$2.49M
Dividend YieldN/A
Average Volume (3M)73.26K
Price to Earnings (P/E)―
Beta (1Y)-0.16
Revenue GrowthN/A
EPS Growth80.99%
CountryUS
Employees7
SectorHealthcare
Sector Strength64
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.36
Shares Outstanding75,462,390
10 Day Avg. Volume97,554
30 Day Avg. Volume73,258
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Galera Therapeutics Business Overview & Revenue Model
Company DescriptionGalera Therapeutics (GRTX) is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics that address unmet medical needs in cancer patients. The company primarily operates in the pharmaceutical and biotechnology sectors, with its core product candidates aimed at treating radiation-induced toxicities and cancers. Galera's lead product candidate, avasopasem manganese, is designed to reduce the severity of radiation-induced severe oral mucositis in patients with head and neck cancer.
How the Company Makes MoneyGalera Therapeutics makes money primarily through the development and potential commercialization of its drug candidates. The company's revenue model is based on obtaining regulatory approvals for its lead candidates, which enables them to either directly market the drugs or enter into licensing agreements and partnerships with larger pharmaceutical companies for distribution and sales. Significant revenue is anticipated from milestone payments, royalties, and licensing fees once its products are approved and commercialized. Additionally, Galera may receive research grants and funding from partnerships that contribute to its earnings as it advances its pipeline of therapeutics.
Galera Therapeutics Financial Statement Overview
Summary
Galera Therapeutics faces significant financial challenges with persistent losses, negative equity, and cash flow difficulties. The lack of revenue and profitability, combined with an unstable balance sheet, pose substantial risks to financial sustainability. The company needs to address these issues to improve its financial health and long-term viability.Income Statement
Galera Therapeutics has consistently reported negative net income, with no revenue growth over the years. The company has not generated revenue from its operations, leading to negative gross and net profit margins. The EBIT and EBITDA margins are also negative, indicating significant operating losses. The lack of revenue growth and continuous losses reflect challenges in achieving profitability.15
Very Negative
Balance Sheet
The company's balance sheet shows a negative stockholders' equity, indicating that liabilities exceed assets, which is a significant financial risk. The debt-to-equity ratio is not meaningful due to negative equity. The equity ratio is negative, highlighting financial instability. This reflects underlying financial weaknesses and potential solvency issues.10
Very Negative
Cash Flow
Despite negative operating cash flow and free cash flow, there is a slight reduction in cash outflows over time. The company has been able to manage its financing activities to support cash needs, but the free cash flow growth remains negative. The ratios of operating and free cash flow to net income are not favorable, indicating cash flow challenges.20
Very Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 88.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -136.00K | -259.00K | -114.00K | -778.00K | -368.00K | -267.00K | EBIT |
| -19.87M | -46.95M | -51.23M | -73.37M | -70.55M | -50.69M | EBITDA |
| -19.37M | -46.69M | -50.61M | -72.56M | -69.01M | -50.69M | Net Income Common Stockholders |
| -19.61M | -59.08M | -62.22M | -87.73M | -74.22M | -51.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 81.52M | 18.26M | 31.60M | 71.22M | 72.78M | 112.29M | Total Assets |
| 88.06M | 26.14M | 44.04M | 83.31M | 84.10M | 123.38M | Total Debt |
| 0.00 | 1.25M | 44.00K | 302.00K | 534.00K | 831.00K | Net Debt |
| -14.81M | -17.01M | -4.22M | -19.56M | -15.34M | -17.52M | Total Liabilities |
| 192.88M | 157.33M | 153.22M | 141.31M | 77.98M | 53.77M | Stockholders Equity |
| -104.82M | -131.19M | -109.18M | -58.00M | 6.12M | 69.61M |
| Cash Flow | Free Cash Flow | ||||
| -9.92M | -44.91M | -43.45M | -68.24M | -59.99M | -47.29M | Operating Cash Flow |
| -9.91M | -44.85M | -43.43M | -67.96M | -59.54M | -46.66M | Investing Cash Flow |
| 3.98M | 27.29M | 23.99M | 5.24M | 36.55M | -27.82M | Financing Cash Flow |
| -232.00K | 31.50M | 3.89M | 66.71M | 20.51M | 78.03M |
Galera Therapeutics Technical Analysis
Negative
0.03
Price Trends
0.04
Negative
0.04
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
40.10
Neutral
12.12
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTX, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.10 is Neutral, neither overbought nor oversold. The STOCH value of 12.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GRTX.
Galera Therapeutics Risk Analysis
Galera Therapeutics disclosed 47 risk factors in its most recent earnings report. Galera Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Galera Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | C$248.22M | ― | 21.91% | ― | 281.24% | 94.17% | |
49 Neutral | $6.86B | 0.72 | -52.93% | 2.49% | 20.83% | 1.11% | |
46 Neutral | $784.63M | ― | -60.44% | ― | 504.79% | 74.24% | |
40 Underperform | $47.13M | ― | 41.08% | ― | -0.55% | 49.85% | |
39 Underperform | $251.19M | ― | -16.20% | ― | 498.72% | 49.92% | |
31 Underperform | $2.49M | ― | 13.71% | ― | ― | 80.99% |
* Healthcare Sector Average
Performance Comparison
GRTX
Galera Therapeutics
0.03
-0.11
-78.57%
AVDL
Avadel Pharmaceuticals
8.12
-8.77
-51.92%
XOMA
Xoma
20.97
-3.08
-12.81%
KPTI
Karyopharm Therapeutics
4.35
-18.30
-80.79%
TSE:FRX
Fennec Pharmaceuticals
9.05
-6.05
-40.07%
Galera Therapeutics Corporate Events
M&A TransactionsBusiness Operations and Strategy
Galera Therapeutics Expands with Nova Pharmaceuticals Acquisition
Positive
Dec 31, 2024
Galera Therapeutics has completed the acquisition of Nova Pharmaceuticals, which focuses on developing a pan-NOS inhibitor to treat resistant forms of breast cancer. The merger shifts Galera’s strategy towards anti-cancer therapeutics, with plans for multiple clinical trials, including a Phase 1/2 trial for metaplastic breast cancer. This acquisition is expected to bolster Galera’s financial and operational capabilities, with support from investors and strategic partnerships to fund developments through 2026.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.